ALFA Finder| Revenue growth | 48% YoY growth for 9M FY'26 reaching ₹426 crores. |
|---|---|
| Margins | EBITDA margin improved to 16% in Q3, up 384 bps. |
| Demand visibility | Strong traction in new brands launched over last 3 years. |
| Management confidence | High; MD emphasizes overachieving conservative internal targets. |
Growth
Q3 Revenue: ₹160.92cr (+57% YoY); 9M Revenue: ₹426cr (+48% YoY). 9M PAT: ₹26.98cr (+96% YoY).
Outlook
Targets 51% revenue from new-age business by 2029-2030; expects 12-18% growth in legacy business.
Risks
Seasonal Q1 weakness; rising finance costs due to working capital needs and new machinery loans.
Last quarter's promises, checked
Delivered
- Legacy business growth 12-18% → delivered ~15-20% (= BEAT)
- New-age growth 20-25% → delivered ~20-25% (= BEAT)
- Full year revenue target ₹550-600cr → on track with 9M ₹426cr (= BEAT)
Partly delivered
- Pet biscuit line start Q3 → production started, revenue impact expected Q4 (= PARTIAL)
Earnings Call filed with BSE, NSE: FREDUN. Summary written with AI assistance from the document.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,506.55
- Market cap
- ₹2,159 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 40.8×Sector 43.8×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Q2 FY27 Results: Net Profit ₹18.6 Cr, Up 97.9% YoY
Fredun Pharmaceuticals Ltd reported revenue from operations of ₹265.9 Cr (+85.2% YoY) and net profit of ₹18.6 Cr (+97.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.6 Cr · +97.9% YoY
Fredun Pharmaceuticals Board Meeting Date
Fredun Pharmaceuticals will hold a board meeting on 05 November 2026 to consider half-year results. Trading window stays closed until 48 hours after results.
Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.